Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.